COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE
<p class="MsoBodyText2" style="margin: 0cm 0cm 6pt; text-align: justify;"><span style="mso-ansi-language: EN-US;" lang="EN-US"><span style="font-size: small;"><span style="font-family: Times New R...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2009-11-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/article/view/4735 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846147025614143488 |
|---|---|
| author | Giuseppina Massini Francesco D'Alo' Angelo Pompucci Stefania Manfrida Mario Balducci Luciana Teofili Stefan Hohaus Luigi Maria Larocca Roberto Marra Sergio Storti |
| author_facet | Giuseppina Massini Francesco D'Alo' Angelo Pompucci Stefania Manfrida Mario Balducci Luciana Teofili Stefan Hohaus Luigi Maria Larocca Roberto Marra Sergio Storti |
| author_sort | Giuseppina Massini |
| collection | DOAJ |
| description | <p class="MsoBodyText2" style="margin: 0cm 0cm 6pt; text-align: justify;"><span style="mso-ansi-language: EN-US;" lang="EN-US"><span style="font-size: small;"><span style="font-family: Times New Roman;">Chemotherapy including high-dose<strong style="mso-bidi-font-weight: normal;"> </strong>methotrexate (HD-MTX), with or without radiotherapy, is standard treatment for primary cerebral nervous system lymphoma (PCNSL). It remains controversial whether addition of other drugs will add to therapeutic efficacy. We report here on 41 patients with PCNSL treated using a combined treatment modality, including HD-MTX (3.5 g/m<sup>2</sup> for 2 cycles) prior to whole brain radiotherapy (WBRT). In 22 patients, the chemotherapy was intensified by adding high-dose cytosine arabinoside (HD-AraC) (2g/m<sup>2</sup> for 4 doses for 2 cycles). Complete remission was obtained in 23 of 34 assessable patients (67%), and overall and disease-free survival rates were 24% and 46%, respectively, without differences between treatment groups. The addition of HD-AraC was complicated by severe infections in 17/22 (77%) patients, resulting in 3 toxic deaths. <span style="mso-bidi-font-weight: bold;">Our study indicates that addition of HD-AraC may not improve clinical outcome in PCNSL, while it increases toxicity. More targeted and less toxic therapies are warranted.</span></span></span></span></p> |
| format | Article |
| id | doaj-art-506f4d2c003143ffb8213a539d6da5b5 |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2009-11-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-506f4d2c003143ffb8213a539d6da5b52024-12-02T00:04:52ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062009-11-0112e2009020e2009020COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCEGiuseppina MassiniFrancesco D'Alo'Angelo PompucciStefania ManfridaMario BalducciLuciana TeofiliStefan HohausLuigi Maria LaroccaRoberto MarraSergio Storti<p class="MsoBodyText2" style="margin: 0cm 0cm 6pt; text-align: justify;"><span style="mso-ansi-language: EN-US;" lang="EN-US"><span style="font-size: small;"><span style="font-family: Times New Roman;">Chemotherapy including high-dose<strong style="mso-bidi-font-weight: normal;"> </strong>methotrexate (HD-MTX), with or without radiotherapy, is standard treatment for primary cerebral nervous system lymphoma (PCNSL). It remains controversial whether addition of other drugs will add to therapeutic efficacy. We report here on 41 patients with PCNSL treated using a combined treatment modality, including HD-MTX (3.5 g/m<sup>2</sup> for 2 cycles) prior to whole brain radiotherapy (WBRT). In 22 patients, the chemotherapy was intensified by adding high-dose cytosine arabinoside (HD-AraC) (2g/m<sup>2</sup> for 4 doses for 2 cycles). Complete remission was obtained in 23 of 34 assessable patients (67%), and overall and disease-free survival rates were 24% and 46%, respectively, without differences between treatment groups. The addition of HD-AraC was complicated by severe infections in 17/22 (77%) patients, resulting in 3 toxic deaths. <span style="mso-bidi-font-weight: bold;">Our study indicates that addition of HD-AraC may not improve clinical outcome in PCNSL, while it increases toxicity. More targeted and less toxic therapies are warranted.</span></span></span></span></p>http://www.mjhid.org/article/view/4735Lymphoma |
| spellingShingle | Giuseppina Massini Francesco D'Alo' Angelo Pompucci Stefania Manfrida Mario Balducci Luciana Teofili Stefan Hohaus Luigi Maria Larocca Roberto Marra Sergio Storti COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE Mediterranean Journal of Hematology and Infectious Diseases Lymphoma |
| title | COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE |
| title_full | COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE |
| title_fullStr | COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE |
| title_full_unstemmed | COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE |
| title_short | COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE |
| title_sort | combined modality treatment including methotrexate based chemotherapy for primary cerebral nervous system lymphoma a single institution experience |
| topic | Lymphoma |
| url | http://www.mjhid.org/article/view/4735 |
| work_keys_str_mv | AT giuseppinamassini combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT francescodalo combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT angelopompucci combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT stefaniamanfrida combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT mariobalducci combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT lucianateofili combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT stefanhohaus combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT luigimarialarocca combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT robertomarra combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience AT sergiostorti combinedmodalitytreatmentincludingmethotrexatebasedchemotherapyforprimarycerebralnervoussystemlymphomaasingleinstitutionexperience |